Who are EMEND's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MK0954, /Duration of Treatment : 16 Weeks, Comparator: MK0517, Comparator: Placebo to aprepitant, Vehicle to AGN-199201, MK0954, /Duration of Treatment : 5 Years, Comparator: Aprepitant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/emend.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

EMEND — Competitive Intelligence Brief

EMEND (EMEND) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurokinin-1 (NK1) receptor antagonist. Area: Oncology.

marketed Neurokinin-1 (NK1) receptor antagonist NK1 receptor (neurokinin-1 receptor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

EMEND (EMEND) — Merck Sharp & Dohme LLC. EMEND (aprepitant) blocks substance P neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EMEND TARGET	EMEND	Merck Sharp & Dohme LLC	marketed	Neurokinin-1 (NK1) receptor antagonist	NK1 receptor (neurokinin-1 receptor)
MK0954, /Duration of Treatment : 16 Weeks	MK0954, /Duration of Treatment : 16 Weeks	Organon and Co	phase 3	Neurokinin-1 (NK1) receptor antagonist	NK1 receptor
Comparator: MK0517	Comparator: MK0517	Merck Sharp & Dohme LLC	phase 3	Neurokinin-1 (NK1) receptor antagonist	NK1 receptor
Comparator: Placebo to aprepitant	Comparator: Placebo to aprepitant	Merck Sharp & Dohme LLC	phase 3	Neurokinin-1 (NK1) receptor antagonist	NK1 receptor
Vehicle to AGN-199201	Vehicle to AGN-199201	Allergan	phase 3	Neurokinin-1 (NK1) receptor antagonist	NK1 receptor
MK0954, /Duration of Treatment : 5 Years	MK0954, /Duration of Treatment : 5 Years	Organon and Co	phase 3	Neurokinin-1 (NK1) receptor antagonist	NK1 receptor
Comparator: Aprepitant	Comparator: Aprepitant	Merck Sharp & Dohme LLC	phase 3	Neurokinin-1 (NK1) receptor antagonist	NK1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurokinin-1 (NK1) receptor antagonist class)

Merck Sharp & Dohme LLC · 4 drugs in this class
Organon and Co · 2 drugs in this class
Allergan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EMEND — Competitive Intelligence Brief. https://druglandscape.com/ci/emend. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab